Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

ELN.MI IT Equity

El.En. - S.P.A.Health Care · FY ends Dec 31
€15.50
-0.12 (-0.77%)
EUR · as of 2026-08-17 · marketstack
2 registered studies · 0 active

Studies where ELN.MI is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

2 interventional · 2 with posted results

government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal AtrophyNCT02085980results2021-06-04The Main Outcome of the Study is the Efficacy of the Laser Procedure, Intended as the Amelioration of 50% of the Severity of the Vaginal Dryness at 12 Months, Compared With BaselineOpen-label · TreatmentNot applicableCompletedDevice: Laser treatmentVulvovaginal Atrophy30Aug 2015actual2021-06-04
TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and RhytidesNCT01859611results2015-03-11Changes to the Surface by Visual and Photographic Analysis.Open-label · TreatmentNot applicableCompletedDevice: TriActive+ RFWrinkles, Rhytides51Jan 2014actual2015-04-07

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19